Natera Inc (NTRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Natera Inc (NTRA) has a cash flow conversion efficiency ratio of 0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($54.79 Million) by net assets ($1.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see NTRA company net worth for the company's overall valuation and market capitalisation.
Natera Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Natera Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Natera Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Natera Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Natera Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Larsen & Toubro Limited
F:LTO
|
N/A |
|
Celestica Inc.
TO:CLS
|
0.162x |
|
Erste Group Bank AG
VI:EBS
|
-0.063x |
|
Argen-X
BR:ARGX
|
0.087x |
|
CITIC Securities Co Ltd
SHG:600030
|
0.221x |
|
Vistra Energy Corp
NYSE:VST
|
0.281x |
|
AutoZone Inc
NYSE:AZO
|
-0.288x |
|
Ambev S.A.
SA:ABEV3
|
0.035x |
Annual Cash Flow Conversion Efficiency for Natera Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Natera Inc from 2012 to 2025. View Natera Inc (NTRA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.71 Billion | $215.30 Million | 0.126x | +10.79% |
| 2024-12-31 | $1.20 Billion | $135.66 Million | 0.113x | +135.17% |
| 2023-12-31 | $765.33 Million | $-246.96 Million | -0.323x | +47.22% |
| 2022-12-31 | $705.74 Million | $-431.50 Million | -0.611x | -19.15% |
| 2021-12-31 | $653.30 Million | $-335.24 Million | -0.513x | -36.71% |
| 2020-12-31 | $486.24 Million | $-182.51 Million | -0.375x | -64.90% |
| 2019-12-31 | $278.71 Million | $-63.44 Million | -0.228x | +89.63% |
| 2018-12-31 | $32.16 Million | $-70.58 Million | -2.195x | +42.98% |
| 2017-12-31 | $25.42 Million | $-97.83 Million | -3.849x | -453.40% |
| 2016-12-31 | $106.48 Million | $-74.05 Million | -0.695x | -239.66% |
| 2015-12-31 | $184.76 Million | $-37.83 Million | -0.205x | -234.43% |
| 2014-12-31 | $-171.34 Million | $10.49 Million | -0.061x | -143.51% |
| 2013-12-31 | $-171.51 Million | $-24.13 Million | 0.141x | +18.57% |
| 2012-12-31 | $-125.61 Million | $-14.90 Million | 0.119x | -- |
About Natera Inc
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehe… Read more